Sequana Medical NV (FRA:2SE) Selling, General, & Admin. Expense: €8.09 Mil (TTM As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2SE Sequana Medical NV FRA:2SE
31 GF Score
Price €0.51
GF Value €0.19
! 12 Warning Signs
View Full Analysis

What is Sequana Medical NV Selling, General, & Admin. Expense?

Sequana Medical NV FRA:2SE 31 Selling, General, & Admin. Expense is €8.09 Mil as of Jun. 2025. GuruFocus rates FRA:2SE with a GF Score™ of 31/100 and a GF Value™ of €0.19. The stock has 12 warning signs investors should review.

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Sequana Medical NV's selling, general, & admin. expense for the six months ended in Jun. 2025 was €4.53 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Jun. 2025 was €8.09 Mil.


Sequana Medical NV  (FRA:2SE) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Sequana Medical NV Selling, General, & Admin. Expense Related Terms


Sequana Medical NV Selling, General, & Admin. Expense Historical Data

* Premium members only.

The historical data trend for Sequana Medical NV's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sequana Medical NV Selling, General, & Admin. Expense Chart

Sequana Medical NV Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.74 7.18 8.93 8.74 7.37

Sequana Medical NV Semi-Annual Data
Dec14 Dec15 Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.56 4.19 3.81 3.56 4.53

FRA:2SE vs ABT, SYK, MDT: Selling, General, & Admin. Expense Comparison

For the Medical Devices subindustry, Sequana Medical NV's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sequana Medical NV Selling, General, & Admin. Expense vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sequana Medical NV's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Sequana Medical NV's Selling, General, & Admin. Expense falls into.


FRA:2SE
31GF Score
Sequana Medical NV FRA:2SE
Selling, General, & Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sequana Medical NV Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €8.09 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling, General, & Admin. Expense of €8.09 Mil mean?
Sequana Medical NV (FRA:2SE) has a Selling, General, & Admin. Expense of €8.09 Mil as of Jun. 2025. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Sequana Medical NV and its competitors.
Is Sequana Medical NV's Selling, General, & Admin. Expense too high?
Sequana Medical NV's current Selling, General, & Admin. Expense is €8.09 Mil. Overall, Sequana Medical NV has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Sequana Medical NV's Selling, General, & Admin. Expense compare to ABT and SYK?
Sequana Medical NV's Selling, General, & Admin. Expense of €8.09 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Medical Devices & Instruments company?
A good Selling, General, & Admin. Expense depends on the Medical Devices & Instruments industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Sequana Medical NV and its competitors. Sequana Medical NV's current Selling, General, & Admin. Expense is €8.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sequana Medical NV stock overvalued right now?
Sequana Medical NV (FRA:2SE) has a current Selling, General, & Admin. Expense of €8.09 Mil. The stock's GF Value™ is €0.19, compared to a current price of €0.51 — trading 169.5% above its estimated fair value. The current Selling, General, & Admin. Expense is €8.09 Mil. Sequana Medical NV's overall GF Score™ is 31/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Sequana Medical NV (FRA:2SE), the current Selling, General, & Admin. Expense is €8.09 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sequana Medical NV (FRA:2SE) Overvalued in 2026?

Based on GuruFocus' analysis, Sequana Medical NV stock appears to be overvalued. The current stock price of €0.51 is trading 169.5% above its estimated GF Value™ of €0.19.

Key valuation signals for FRA:2SE:

  • Selling, General, & Admin. Expense: €8.09 Mil
  • GF Value™: €0.19 vs. price of €0.51 (169.5% above fair value)
  • GF Score™: 31/100 with 12 warning signs

No single metric tells the full story. See the FRA:2SE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sequana Medical NV Business Description

Other Exchanges 2SE:GermanySEQUA:Belgium
Address Kortrijksesteenweg 1112, bus 102, Sint-Denijs-Westrem, Ghent, BEL, 9051
Sequana Medical NV is a commercial-stage medical device company focused on the development of treatment solutions for the management of fluid overload in liver disease, malignant ascites, and heart failure. The company's products include an alfa pump, which provides a treatment solution for the long-term management of liver refractory ascites and malignant ascites with safety, efficacy, and quality of life benefits demonstrated in multiple clinical studies. The company's geographical segments include Switzerland, Germany, the United Kingdom, France, and the Rest of the world, out of which Germany accounts for the majority of the revenue.
31GF Score

Get the complete analysis for FRA:2SE

Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.51
Price
€0.19
GF Value